Nektar Therapeutics (NASDAQ:NKTR) Upgraded to “Hold” at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) from a sell rating to a hold rating in a research report report published on Sunday.

A number of other equities analysts have also weighed in on the stock. HC Wainwright upped their price target on shares of Nektar Therapeutics from $165.00 to $185.00 and gave the stock a “buy” rating in a research report on Monday, April 20th. William Blair upgraded shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 10th. Citigroup upped their price target on shares of Nektar Therapeutics from $123.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, April 21st. B. Riley Financial reiterated a “buy” rating and issued a $150.00 price target (up from $105.00) on shares of Nektar Therapeutics in a research report on Monday, February 23rd. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Nektar Therapeutics in a research report on Wednesday, April 22nd. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $149.63.

Check Out Our Latest Research Report on NKTR

Nektar Therapeutics Stock Performance

Shares of NKTR stock opened at $70.62 on Friday. The stock has a market cap of $2.39 billion, a P/E ratio of -8.39 and a beta of 1.24. Nektar Therapeutics has a 12 month low of $7.99 and a 12 month high of $109.00. The company has a 50 day simple moving average of $78.32 and a two-hundred day simple moving average of $61.59.

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.58) by ($0.24). The firm had revenue of $10.86 million during the quarter, compared to the consensus estimate of $10.69 million. Nektar Therapeutics had a negative return on equity of 85.40% and a negative net margin of 284.18%. As a group, equities analysts forecast that Nektar Therapeutics will post -9.65 earnings per share for the current year.

Insider Buying and Selling at Nektar Therapeutics

In related news, CEO Howard W. Robin sold 423 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $73.00, for a total transaction of $30,879.00. Following the completion of the transaction, the chief executive officer owned 75,489 shares in the company, valued at approximately $5,510,697. This represents a 0.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Nektar Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of NKTR. BNP Paribas Financial Markets boosted its position in shares of Nektar Therapeutics by 93.8% during the third quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 210 shares during the last quarter. KBC Group NV bought a new position in shares of Nektar Therapeutics during the first quarter worth $52,000. Headlands Technologies LLC bought a new position in shares of Nektar Therapeutics during the second quarter worth $65,000. State of Wyoming bought a new position in shares of Nektar Therapeutics during the first quarter worth $67,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in Nektar Therapeutics during the first quarter valued at $68,000. Institutional investors own 75.88% of the company’s stock.

About Nektar Therapeutics

(Get Free Report)

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.

Further Reading